Abbott Laboratories (ABT) Aktsia Kursus
Abbott Laboratories Kursus
Viimase 19 aasta jooksul kasvas Abbott Laboratories käive 3,6 % aastas ja jõudis 44,33 B USD-ni. Kasum aktsia kohta kasvas 6,6 % aastas viimase 19 aasta jooksul. Abbott Laboratories netomarginaal 14,7 % on langenud võrreldes 16,4 %-ga mõni aasta tagasi. Tänase hinna juures on dividenditootlus umbes 2,29 %. Väljamaksesuhe on umbes 63 % kasumist. Dividend kasvas 3,8 % aastas viimase 19 aasta jooksul. Abbott Laboratories 12 kuu konsensuse hinnasiht on 120,00 USD, umbes üle kurssi 16,5 %. 33 analüütikust 26 soovitab osta — üldine konsensus on Osta.
Abbott Laboratories aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Abbott Laboratories ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Abbott Laboratories aktsia kohta
Abbott Laboratories is a renowned healthcare company with a strong business model focused on providing a diverse range of medical products, diagnostics, nutritional supplements, and pharmaceuticals. By combining technological advancements with innovative research, Abbott aims to enhance the quality of life for individuals worldwide. With a comprehensive portfolio spanning diverse healthcare sectors, including diagnostics, nutrition, diabetes care, medical devices, and branded generic pharmaceuticals, Abbott Laboratories strives to improve patient outcomes and deliver sustainable growth. Through its commitment to scientific excellence and dedication to meeting evolving healthcare needs, Abbott Laboratories has established itself as a trusted leader in the global healthcare industry.
Abbott Laboratories is primarily active in the healthcare industry.
The main competitors of Abbott Laboratories in the market are Johnson & Johnson, Pfizer, and Roche Holding AG.
Abbott Laboratories is a renowned American healthcare company, known for providing a diverse range of medical, pharmaceutical, and nutritional products. Founded in 1888 by Dr. Wallace C. Abbott, the company initially focused on producing pharmaceuticals, including the widely successful alkaloid-based pain reliever, Abbott's ABC Liniment. Over the years, Abbott Laboratories has expanded its portfolio, venturing into areas such as diagnostics, medical devices, and nutrition. The company's commitment to innovation is evident through breakthroughs like the development of the first HIV blood-screening test. Today, Abbott Laboratories continues to play a crucial role in improving health outcomes worldwide, with its cutting-edge technology and a focus on delivering quality healthcare solutions.
Abbott Laboratories has achieved several significant milestones throughout its history. One major milestone was the development and commercialization of the first-ever HIV blood screening test, which greatly contributed to safer transfusions and the prevention of the spread of HIV. Additionally, Abbott Laboratories introduced breakthrough medical devices, such as the FreeStyle® Libre system, a continuous glucose monitoring system for diabetes management. The company also played a crucial role in the fight against COVID-19 by developing rapid diagnostic tests for the virus. Furthermore, Abbott Laboratories has consistently been recognized for its commitment to innovation and sustainability, making it a leading healthcare company globally.
Abbott Laboratories is primarily present in multiple countries and regions worldwide. The company operates in more than 160 countries, including the United States, Canada, Europe, Asia-Pacific, Latin America, and the Middle East. With a strong global footprint, Abbott Laboratories has established itself as a leading healthcare company in various markets, delivering innovative medical products, diagnostics, nutritionals, and pharmaceuticals to improve people's health and well-being.
Abbott Laboratories is committed to its core values of putting patients first, serving customers with innovative solutions, and operating with integrity in all aspects of its business. The company's corporate philosophy centers around improving life through the development of groundbreaking technologies and products. Abbott Laboratories prides itself on its dedication to delivering reliable healthcare solutions, fostering collaboration with healthcare professionals, and investing in research and development to address unmet medical needs. With a focus on providing high-quality and accessible healthcare options, Abbott Laboratories strives to create positive impacts in communities worldwide through its diverse portfolio of medical devices, diagnostics, nutrition, and pharmaceutical products.
Analüütikud määravad Abbott Laboratories aktsiale keskmiseks hinnasihi 120,85 USD (mediaan: 120,00 USD), mis on +16,3 % viimase hinna suhtes. Konsensus põhineb 33 analüütiku hinnangul.
33 analüütikut hindavad praegu Abbott Laboratories aktsiat: 26 soovitab osta, 7 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Abbott Laboratories teenib tulu 49,98 B USD ja kasumit aktsia kohta 5,52 USD.
Praeguse kursiga kaubeldakse Abbott Laboratories aktsiaga 93,81 EUR (103,00 USD) juures.
Abbott Laboratories aktsia (ABT) on noteeritud 9 börsil, sh: NYSE (ABT), London (0Q15.L), SIX (Zürich) (ABT.SW), XETRA (ABL.DE), Frankfurt (ABL.F), München (ABL.MU), Düsseldorf (ABL.DU), Hamburg (ABL.HM).
Abbott Laboratories is a global company specializing in the development, manufacturing, and marketing of health products and services. Its business model is divided into different divisions that focus on the needs of patients, doctors, and healthcare systems. The divisions of Abbott Laboratories include Diagnostics, Medical Devices, Nutrition, and Pharmaceutical. The company aims to continuously develop innovative technologies and products to improve healthcare, and it offers a wide range of services and support programs for patients. Abbott Laboratories has established a strong market position and global presence in over 160 countries since its establishment in 1888. It also pursues a successful acquisition strategy to expand its product portfolio, such as the acquisition of St. Jude Medical in 2017 to enhance its cardiovascular products and services. Overall, Abbott Laboratories aims to improve healthcare and meet the needs of patients, doctors, and healthcare systems through its comprehensive strategy focused on developing innovative products, expanding into new markets, and increasing efficiency.
oodatav Abbott Laboratories käive on 49,98 B USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.
oodatav Abbott Laboratories kasum on 9,64 B USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Abbott Laboratories jaoks on praegu 18,66. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Abbott Laboratories aktsia väärtust.
Kursuse ja müügimahu suhe (P/S) Abbott Laboratories jaoks on praegu 3,60. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Abbott Laboratories aktsia jaoks.
Eulpooli kvaliteedinäitaja Abbott Laboratories jaoks on 6/10.
Abbott Laboratories ISIN on US0028241000. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Abbott Laboratories WKN on 850103. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Abbott Laboratories ticker on ABT. Ticker-sümbol kasutatakse Abbott Laboratories aktsiate kauplemiseks börsil.
Abbott Laboratories aktsia
Abbott Laboratories konkurendid
Abbott Laboratories Börsiticker
Abbott Laboratories FIGI
Kõik teised näitajad ja analüüsid Abbott Laboratories kohta sügavamalt
Meie Abbott Laboratories-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Abbott Laboratories. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse:


